ERBB2 and breast neoplasm: More recently, Park et al (2002) demonstrated that anti-Her2 immunoliposomes exhibit excellent antitumour efficacy in vivo against Her2-overexpressing breast tumour cells, while the efficacy was almost the same as that of nonimmunoliposomes against low-Her2-expressing MCF-7 cells (1 × 104 receptor cell−1).